The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

310 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-13

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* To identify the incidence of LIT among critically ill patients, as limited studies have only addressed this population.
* To evaluate the impact of several factors on the incidence of LIT, the time to onset of LIT, and the time to recovery of platelets.
* To study the effect of concurrent medications (enoxaparin, unfractinated heparin, piperacillin, carbapenems, tigecycline, fluconazole or voriconazole, digoxin, amiodarone, acetaminophen, tirofiban, statins, and antiepileptics) frequently used in critically ill patients on the incidence of LIT.
* To investigate the impact of possible medications with an antioxidant effect on the prevention of LIT.
* To assess the impact of LIT on composite end point (mortality, bleeding, and length of stay)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients

NCT05944458

Linezolid Antioxidant Thrombocytopenia +2 more

COMPLETED PHASE4

This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

NCT02859909

Immune Thrombocytopenia

COMPLETED PHASE3

rhTPO in Critical Patients With Thrombocytopenia

NCT02094248

Sepsis Thrombocytopenia

UNKNOWN PHASE2/PHASE3

Characterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia

NCT06033300

Heparin-induced Thrombocytopenia HIT Platelet Activation +5 more

RECRUITING NA

Value of Platelet Indices as Predictive Factor in Thrombocytopenia

NCT05116033

Main Focus of the Study

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombocytopenia; Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single arm group

Adult critically ill patients admitted to ICU for different indications

Linezolid 600 mg

Intervention Type DRUG

Linezolid 600mg injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Linezolid 600 mg

Linezolid 600mg injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All adult patients, age \> or = 18 years old, admitted to the ICU with different indications.
* candidates for intravenous linezolid therapy for \> or =1 day.

Exclusion Criteria

* Taking any myelosuppressive drug.
* Baseline platelets \< 50000.
* Patients with hematological malignancy.
* COVID-19 patients.
* Patients with immune thrombocytopenia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No